AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 22 min read$CERS

Jensen Chrystal sold $72K of CERS

Jensen Chrystal (Chief Legal Officer) sold 24,329 shares of CERUS CORP (CERS) at $2.94 on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jensen Chrystal
Published Jul 2, 2026, 11:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CERS
Neutral
high confidence
Mentioned
$CERS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CERSNeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and post-transaction holdings of the Chief Legal Officer under a pre-arranged 10b5-1 plan; it is not accompanied by any new operational or financial update.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a major repricing without accompanying fundamental news.

03

What to watch

The filing does not state motives beyond the 10b5-1 plan; without additional context (e.g., other insider buys/sells, volume vs. typical), signal quality is low.

Relevance 2/10Novelty 3/10Timing: Filed July 2 after-hours; reflects June 30 sale details.

Background

The article is an SEC Form 4 insider transaction disclosure for Cerus Corp (CERS).

Company-level read

Ticker impact

$CERSNeutralHigh confidence
Context

Cerus Corp disclosed a Form 4 showing Chief Legal Officer Jensen Chrystal sold 24,329 shares at $2.9429 on June 30 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing.

Evidence & confidence

The filing is a standard Form 4 open-market sale with 10b5-1 pre-arrangement; it does not include new company fundamentals, guidance, or regulatory/operational events.

Market effects

Sector

Minimal—this is company-specific insider transaction disclosure, not a sector catalyst.

Regional

None—no broader regional linkage indicated.

Global

None—no international deal/regulatory action mentioned.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with management’s view of near-term risk; traders may still watch for follow-on selling.

Key entities

  • issuer
    Cerus Corp

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Jensen Chrystal

    Chief Legal Officer who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CERS insider trading history →

Related articles

NOV 3
$CERSMed

Cerus Q3 Earnings Call Highlights

Cerus reported Q3 EMEA revenue growth of 5%, impacted by geopolitical and currency headwinds. The company's RedeS study met primary efficacy endpoints, with full analysis expected soon. Cerus reaffirmed 2026 revenue guidance of $229M-$231M and reported positive adjusted EBITDA. The company is addressing regulatory questions from the FDA and ANSM. Cerus aims for GAAP profitability and plans to refresh its shelf registration statement.

finance.yahoo.com2 min
NOV 2
$CERSMed

Cerus: Q3 Earnings Snapshot

Cerus Corp. reported a Q3 loss of $550,000, or less than 1 cent per share, with revenue of $57.7 million. The company expects full-year revenue between $229 million and $231 million.

finance.yahoo.com1 min
NOV 2
$CERSMedAI 8/10

Cerus' blood-safety system meets main goal in late-stage trial

Cerus Corp reported that its Intercept blood-safety technology met the main goal in a late-stage trial, showing treated red blood cells performed as well as conventional ones in transfusions. The study found no significant difference in adverse events, though some patients developed temporary antibodies. The technology is not yet FDA-approved.

finance.yahoo.com4 min
NOV 2
$CERSMed

Cerus Corporation Announces Third Quarter 2026 Financial Results

CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Third Quarter 2026 Financial Results Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red bl

SEC EDGAR 8-K2 min
NOV 2
MedAI 8/10

Treated red blood cells performed no worse than conventional cells on hemoglobin gains in Cerus’ Phase 3 trial.

Cerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.

stocktitan.net2 min